Growth Metrics

Nurix Therapeutics (NRIX) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 0.78.

  • Nurix Therapeutics' Equity Ratio fell 56.14% to 0.78 in Q4 2025 from the same period last year, while for Nov 2025 it was 0.78, marking a year-over-year decrease of 56.14%. This contributed to the annual value of 0.78 for FY2025, which is 56.14% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Equity Ratio of 0.78 as of Q4 2025, which was down 56.14% from 0.71 recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Equity Ratio high stood at 0.79 for Q4 2024, and its period low was 0.54 during Q1 2024.
  • In the last 5 years, Nurix Therapeutics' Equity Ratio had a median value of 0.74 in 2023 and averaged 0.72.
  • Per our database at Business Quant, Nurix Therapeutics' Equity Ratio plummeted by 2710.52% in 2024 and then soared by 4488.31% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Equity Ratio (Quarter) stood at 0.72 in 2021, then rose by 1.5% to 0.73 in 2022, then fell by 22.63% to 0.56 in 2023, then surged by 39.64% to 0.79 in 2024, then dropped by 0.56% to 0.78 in 2025.
  • Its Equity Ratio was 0.78 in Q4 2025, compared to 0.71 in Q3 2025 and 0.76 in Q2 2025.